In the first edition of Samsung Bioepis’ Biosimilar Market Report, the company outlined the current state of the US biosimilars market and how increasing adoption has had an impact on pricing changes for biosimilars and their reference products.
In the first edition of Samsung Bioepis’ Biosimilar Market Report, the company outlined the current state of the US biosimilars market and changes in prices for biosimilars and their reference products.
Since 2013, biosimilars have generated $56 billion in savings for the US health care system, and over the next 5 years, savings are expected to reach $181 billion. The report, which will be updated each quarter, outlines how pricing and adoption has changed over time in different disease states, including oncology, supportive care, immunology, endocrinology, and ophthalmology.
“Biosimilars continue to play a crucial role in driving down health care costs in the US and a collaborative approach is fundamental for the sustainable growth of the US biosimilar market…. We hope to offer the resource as useful context in order to bring up-to-date information to the forefront of the biosimilar market landscape,” wrote Thomas Newcomer, vice president and head of market access at Samsung Bioepis US, in the report’s foreword.
Of the 40 FDA-approved biosimilars across 11 originators, only 28 have launched on the US market, including 7 adalimumab biosimilars that are expected to launch in July 2023. Biosimilars have gained an average 53% market share in 3 years post launch of the first biosimilar in each class. (Table)
Additionally, the average slaes price (ASP) declined by an average of 41% over the same time frame; however, bevacizumab and filgrastim ASPs have seen increases following new biosimilar launches.
Across oncology, the stated wholesale acquisition cost (WAC) has gone down between 10% and 25% across the trastuzumab, bevacizumab, and rituximab markets. The ASP has gone down by over 60% across the oncology space.
Despite some modest biosimilar competition and lowered ASPs in the supportive care space, originators Neulasta (pegfilgrastim) and Epogen/Procrit (epoetin alfa) have been able to retain market share.
The immunology and ophthalmology spaces have experienced little uptake so far. Although infliximab biosimilars have launched with progressively lower WACs (between 19% and 59% lower than the originator), uptake has been slower than expected. Only 2 ophthalmology biosimilars, both ranibizumab products, have launched at a WAC of 30% and 42% lower than the originator. However, they launched in late 2022 and ophthalmologists are wary about using them, so uptake is low.
In 2023, at least 8 adalimumab biosimilars will launch in the United States. As of the publishing of the report, only 1 is on the market (Amjevita), and it launched with 2 WACs (5% and 55% lower than the originator). The biosimilar has not experienced much uptake so far.
In the insulin space, the 5 variations of Lantus (insulin glargine) biosimilars, including Basaglar, Toujeo, and unbranded Lantus, have WACs ranging from 4% higher to 66% lower than Lantus. Uptake of insulin biosimilars is low because manufacturers have struggled to get their products onto formularies.
Samsung Bioepis found that increased biosimilar usage resulted in ASP erosion, which indicated a strong relationship between lower biosimilar prices and higher market share. Oncology had the steepest correlation, demonstrating that the oncology space is more sensitive to pricing changes than the supportive care or immunology spaces.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer
March 12th 2024A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.